NCT06616181

Brief Summary

This randomized controlled trial aims to analyze the effects of anodal tDCS applied over the primary motor cortex and dorsolateral prefrontal cortex combined with a tele-rehabilitation exercise program in patients with fibromyalgia. The study will compare these effects with each other and with placebo tDCS on the following variables: pain intensity, pain mechanosensitivity, quality of life, fatigue, anxiety, depression, sleep quality, pain catastrophizing, functional capacity, isometric strength, and exercise adherence. Secondary objectives include:

  • Describing the sociodemographic, clinical, and functional characteristics of fibromyalgia patients.
  • Comparing exercise intensity levels between patients receiving tDCS on M1, DLPFC, and placebo stimulation.
  • Reporting any adverse effects of the intervention. Adult participants with fibromyalgia will be randomized into three groups: a) anodal tDCS over M1 + telerehabilitation, b) anodal tDCS over DLPFC + telerehabilitation, and c) sham-tDCS + telerehabilitation. The intervention will last for 12 weeks. The telerehabilitation exercise program will include an aerobic phase and a resistance phase, with four intensity levels regulated based on the Borg Rating of Perceived Exertion (0-10). The program will be conducted remotely through phone contact, with materials and videos provided to guide exercise execution. tDCS will be applied once per week for 20 minutes at 2 mA, either over M1 or DLPFC. The dependent variables-pain intensity, fibromyalgia impact, fatigue, anxiety and depression levels, pain catastrophizing, sleep quality, functional capacity, and isometric muscle strength-will be collected in the week prior to the intervention, the week following the intervention, and 12 weeks after its completion. Additionally, pain intensity, fibromyalgia impact, fatigue severity, anxiety and depression levels, pain catastrophizing, and sleep quality will be evaluated during the 6th week of the intervention. Exercise intensity, exercise adherence, and any adverse effects related to the intervention will be recorded weekly.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for not_applicable

Timeline
7mo left

Started Dec 2024

Typical duration for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress72%
Dec 2024Dec 2026

First Submitted

Initial submission to the registry

September 22, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 27, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

September 27, 2024

Status Verified

September 1, 2024

Enrollment Period

1 year

First QC Date

September 22, 2024

Last Update Submit

September 24, 2024

Conditions

Keywords

tDCSexercisetelerehabilitationhome-based exercisefibromyalgia

Outcome Measures

Primary Outcomes (1)

  • Pain intensity

    Pain intensity will be assessed using the Visual Analog Scale (VAS). Participants will indicate their pain intensity by placing a perpendicular mark on a 100 mm straight line, where the left end represents \'no pain\'; and the right end represents \'the worst imaginable pain\'. Pain intensity is quantified by measuring the distance in mm from the left end of the line using a ruler.

    At pre-intervention, at weeks 12 and 24.

Secondary Outcomes (9)

  • Pain mechanosensitivity

    At pre-intervention, at weeks 12 and 24.

  • Fatigue

    At pre-intervention, at weeks 12 and 24.

  • Sleep Quality

    At pre-intervention, at weeks 12 and 24.

  • Pain Catastrophizing

    At pre-intervention, at weeks 12 and 24.

  • Isometric Strength

    At pre-intervention, at weeks 12 and 24.

  • +4 more secondary outcomes

Other Outcomes (2)

  • Exercise intensity

    At weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.

  • Adverse events

    At weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.

Study Arms (3)

Anodal tDCS over M1 + telerehabilitation

EXPERIMENTAL

tDCS over M1: The anode will be placed over the left M1 (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks. Telerehabilitation Exercise: Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance exercise will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact.

Device: Anodal tDCS over M1Behavioral: Exercise telerehabilitation

Anodal tDCS over DLPFC + telerehabilitation

EXPERIMENTAL

tDCS over DLPFC: The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC) (F3), and the cathode will be positioned over the contralateral supraorbital area (F8). Once the electrodes are positioned, active tDCS will be applied at 2mA for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks. Tele-rehabilitation Exercise: Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance exercise will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact.

Device: Anodal tDCS over DLPFCBehavioral: Exercise telerehabilitation

sham-tDCS + telerehabilitation

PLACEBO COMPARATOR

Sham tDCS: The same electrode placement protocol used for the active tDCS M1 group will be followed in this group. Stimulation will begin with a 30-second ramp-up to reach an intensity of 2 mA, immediately followed by a 30-second ramp-down to 0 mA. This stimulation will be repeated at the beginning and end of the session. Similar to the active tDCS groups, each session will last 20 minutes. Telerehabilitation Exercise: Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance exercise will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact.

Behavioral: Exercise telerehabilitation

Interventions

The anode will be placed over the left M1 (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.

Anodal tDCS over M1 + telerehabilitation

The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC) (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.

Anodal tDCS over DLPFC + telerehabilitation

Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance training will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact.

Anodal tDCS over DLPFC + telerehabilitationAnodal tDCS over M1 + telerehabilitationsham-tDCS + telerehabilitation

Eligibility Criteria

Age30 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 30 and 70 years.
  • Medical diagnosis of fibromyalgia.Compliance with the latest diagnostic criteria from the American College of Rheumatology.
  • Stable medication for at least 12 weeks prior to the start of the study.
  • Ability to use communication technologies, such as smartphones and computers.
  • Capacity to participate in an aerobic exercise program.
  • Access to the internet.
  • Proficiency in oral and written Spanish.
  • Signed informed consent

You may not qualify if:

  • Severe psychiatric disorders.
  • Uncontrolled cardiovascular, respiratory, metabolic, neurological, rheumatic, or hepatic diseases.
  • Concurrent chronic inflammatory or autoimmune disease.
  • Contraindications to physical activity.
  • Metal implants in the head.
  • History of cancer, brain tumor, epileptic episodes, stroke, severe head trauma, or brain surgery.
  • Pregnancy or lactation.
  • Use of carbamazepine in the past 6 months.
  • Changes in medication during the study.
  • Participation in other non-pharmacological conservative therapies (e.g., hydrotherapy, electrotherapy, manual therapy, exercise, dry needling) during the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

FibromyalgiaMotor Activity

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesBehavior

Central Study Contacts

Ignacio Hernando Garijo

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Statistician
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD physiotherapist

Study Record Dates

First Submitted

September 22, 2024

First Posted

September 27, 2024

Study Start

December 1, 2024

Primary Completion

December 1, 2025

Study Completion (Estimated)

December 1, 2026

Last Updated

September 27, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share